Effect of BGC20-1531 on Headaches Induced by Prostaglandin E2
Author Information
Author(s): Antonova Maria, Wienecke Troels, Maubach Karen, Thomas Emma, Olesen Jes, Ashina Messoud
Primary Institution: Danish Headache Center and Department of Neurology, Faculty of Health Sciences, Glostrup Hospital, University of Copenhagen
Hypothesis
Can the EP4 receptor antagonist BGC20-1531 prevent headaches and arterial dilation induced by Prostaglandin E2?
Conclusion
BGC20-1531 did not prevent headaches or arterial dilation caused by Prostaglandin E2 in healthy volunteers.
Supporting Evidence
- BGC20-1531 did not show a significant effect on headache intensity compared to placebo.
- Putative therapeutic exposures of BGC20-1531 were not reached in all volunteers.
- Other EP receptors may be involved in PGE2-induced headache and dilation.
Takeaway
The study tested a new drug to see if it could stop headaches caused by a substance in the body, but it didn't work as hoped.
Methodology
A randomized, double-blind, placebo-controlled, three-way crossover study with eight healthy volunteers receiving different doses of BGC20-1531 and placebo.
Potential Biases
Potential bias due to the small number of participants and variability in drug exposure.
Limitations
The study had a small sample size and some participants did not reach therapeutic drug levels.
Participant Demographics
8 healthy volunteers (5 male, 3 female), mean age 24 years.
Statistical Information
Statistical Significance
p>0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website